MET and cancer: Accumulating data indicate that lncRNAs act as competing endogenous RNAs (ceRNAs) to reduce the activity of microRNAs (miRNAs) through shared miRNA response elements (MREs) in cancer.14, 15 For example, NEAT1 facilitates tumour progression in lung cancer,16 and laryngeal squamous cell carcinoma by miR‐107/CDK6 axis17 and in pancreatic cancer by miR‐335/c‐met axis,18 and contributes to the chemo‐resistance to gemcitabine in cholangiocarcinoma.19 These studies unveil the key regulation crosstalk between NEAT1 and miRNAs in cancer.